{
    "clinical_study": {
        "@rank": "33639", 
        "arm_group": [
            {
                "arm_group_label": "Botulinum toxin", 
                "arm_group_type": "Experimental", 
                "description": "Single intra-articular injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single intra-articular injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety and tolerability of the drug product at\n      each dose level."
        }, 
        "brief_title": "Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee", 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Osteoarthritis of the knee\n\n          -  Fully weight bearing in the index knee with or without the need for\n             assistive/orthopaedic devices\n\n          -  Pain score \u226540 mm of the index knee\n\n          -  Committing to continue using their assistive/orthopaedic device throughout the study\n             using the same regimen\n\n        Exclusion Criteria:\n\n          -  Any infection in the index knee or inflammatory skin disease or other inflammatory\n             diseases at the index knee or the anticipated injection site\n\n          -  Surgery on the symptomatic knee within the previous 12 months or arthroscopy in the\n             index knee in the past 3 months\n\n          -  Any painful orthopaedic disorder of the back or hip which is likely to interfere with\n             the safety or efficacy assessments\n\n          -  A joint disorder other than osteoarthritis in the index knee which could potentially\n             interfere with the safety or efficacy assessments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139319", 
            "org_study_id": "43QM1309"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botulinum toxin", 
                "intervention_name": "Botulinum toxin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "last_name": "Q-Med AB", 
            "phone": "+46184749000"
        }, 
        "overall_official": {
            "affiliation": "Q-Med AB", 
            "last_name": "Q-Med AB", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence and severity of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Q-Med AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Q-Med AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}